Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Scand J Surg ; 105(1): 56-63, 2016 Mar.
Article in English | MEDLINE | ID: mdl-25869306

ABSTRACT

BACKGROUND AND AIMS: Unicompartmental knee arthroplasty is considered as an alternative to total knee arthroplasty for patients who have osteoarthritis limited to the medial compartment of the knee. The aim of this retrospective study was to find out clinical and radiological outcomes and related complications using the Oxford phase 3 prosthesis at a small-volume center. MATERIAL AND METHODS: In all, 95 Oxford unicompartmental knee arthroplasties (87 patients) were performed between 2000 and 2010 in North Karelia Central Hospital. Of these, five patients had undergone revision surgery. In all, 52 unicompartmental knee arthroplasties (46 patients) participated in this study. The mean age of patients was 61.4 years, and 78.2% of patients were females. Pain and function levels were evaluated by using the Knee Society score. Radiographic analyses were performed on preoperative and postoperative and follow-up radiographs. RESULTS AND CONCLUSIONS: The mean follow-up time was 6.5 years, and the Kaplan-Meier estimated 9-year implant survival rate was 88.9% (95% confidence interval = 78.7%-99.1%). The median Knee Society score of 77 (range: 18-93) at follow-up was considered good (range: 70-79). In this study, we found out that medial knee pain remains in 10% of unicompartmental knee arthroplasties several years after surgery, although the reason for the pain remained unclear. These mid-term results are promising, and good results can be achieved also at a small-volume center when strict patient selection is followed.


Subject(s)
Arthroplasty, Replacement, Knee , Osteoarthritis, Knee/surgery , Aged , Aged, 80 and over , Arthroplasty, Replacement, Knee/instrumentation , Female , Follow-Up Studies , Humans , Kaplan-Meier Estimate , Knee Prosthesis , Male , Middle Aged , Osteoarthritis, Knee/diagnostic imaging , Radiography , Reoperation , Retrospective Studies , Treatment Outcome
2.
Scand J Surg ; 99(1): 32-7, 2010.
Article in English | MEDLINE | ID: mdl-20501356

ABSTRACT

BACKGROUND AND AIMS: Periprosthetic bone loss, especially in the proximal part of the femur, is common after cemented and uncemented total hip arthroplasty (THA). Short-term studies suggest that bisphosponates can minimize this bone loss related to stress-shielding phenomenon. The aim of the present randomized study was to investigate whether the positive effect of a 6 months alendronate treatment postoperatively still exists at five-year follow up. MATERIALS AND METHODS: Sixteen uncemented primary THA patients were randomized to receive either 10mg alendronate + 500 mg calcium (n = 7) or 500 mg calcium only (n = 9) daily for 6 months postoperatively. Periprosthetic bone mineral density (BMD) was measured with the dual X-ray absorptiometry (DXA) postoperatively and at 6, 12, 24, 36 and 60 months follow-up. RESULTS: At the 5-year follow up, the calcium group showed mean BMD decreases of 23.1% (SD 14.6) in the proximal part of the femur (prROI) and 9.6% (SD 14.9) in total femoral regions of interest (totROI). In the alendronate group the corresponding BMD decreases were 13.6% (SD 19.0) and 3.9% (SD 7.6) respectively. The positive effect of alendronate was already demonstrated during the first six months postoperatively. Subsequently the bone loss was equal in both groups, and the 5-year BMD changes were not significantly different between the groups. CONCLUSIONS: Alendronate seems to decrease early periprosthetic bone loss after arthroplasty but this pilot study could not provide enough evidence that the positive effect noted in the early postoperative period is still maintained 5 years after the operation.


Subject(s)
Alendronate/therapeutic use , Arthroplasty, Replacement, Hip/adverse effects , Bone Density Conservation Agents/therapeutic use , Bone Resorption/prevention & control , Hip Prosthesis/adverse effects , Osteoarthritis, Hip/surgery , Aged , Bone Density , Bone Resorption/diagnosis , Bone Resorption/etiology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Osteoarthritis, Hip/complications , Osteoarthritis, Hip/pathology , Pilot Projects , Prospective Studies , Time Factors , Treatment Outcome
3.
Calcif Tissue Int ; 71(6): 472-7, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12370800

ABSTRACT

Undesired bone loss around implants is considered to occur mainly because of a stress-shielding phenomenon. Bone surrounding the total knee arthroplasty (TKA) adjusts its mineral density and structure to meet new mechanical demands. Immobilization, in combination with local operative trauma to the bone and soft tissues, has an additional impact on bone loss. The clinical survival of TKA is associated with the quality and quantity of the surrounding bone environment. Poor bone quality and quantity may predispose to aseptic implant loosening and periprosthetic fractures. We investigated the efficacy of oral bisphosphonate (alendronate, Fosamax) with calcium (Calcichew) for the inhibition of early bone mineral density (BMD) loss after TKA in a prospective, randomized, one-year follow-up study. Periprosthetic BMD changes were measured with fan-beam dual-energy X-ray absorptiometry (DXA) in 19 patients with knee osteoarthrosis. Patients (n = 8) treated with 10 mg alendronate and 500 mg calcium daily maintained distal femoral BMD values close to the baseline values (P > 0.04), while patients receiving only 500 mg of calcium daily (n = 11) showed significant bone loss during the one-year follow-up (P < 0.015). The treatment groups differed significantly in metaphyseal anterior, posterior, diaphyseal, and metaphyseal total regions of interest (ROIs) (repeated measures ANOVA analyses, P = 0.019, P = 0.010, P = 0.022, and P = 0.024, respectively). Our results indicate that oral alendronate reduces early postoperative periprosthetic bone loss significantly. This therapeutic strategy may improve the results and longevity of primary total knee arthroplasties.


Subject(s)
Alendronate/therapeutic use , Arthroplasty, Replacement, Knee , Bone Resorption/drug therapy , Calcium/therapeutic use , Osteoarthritis, Knee/therapy , Postoperative Complications , Absorptiometry, Photon , Aged , Bone Density , Bone Resorption/etiology , Disability Evaluation , Drug Therapy, Combination , Female , Hip Joint/diagnostic imaging , Humans , Male , Middle Aged , Osteoarthritis, Knee/complications , Osteoarthritis, Knee/physiopathology , Prospective Studies , Severity of Illness Index
4.
J Bone Miner Res ; 16(11): 2126-31, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11697810

ABSTRACT

Periprosthetic bone loss, especially in the proximal part of the femur, is common after cemented and uncemented total hip arthroplasty (THA). Bone loss can be progressive and, in the extreme, may threaten survival of the prosthesis. To study whether alendronate therapy can reduce bone loss adjacent to prostheses, 13 uncemented primary THA patients were randomized to the study. They received 10 mg alendronate + 500 mg calcium (n = 8) or 500 mg calcium only (n = 5) daily for 6 months follow-up after THA. Periprosthetic bone mineral density (BMD) was measured with dual energy X-ray absorptiometry (DXA). Decreases in periprosthetic BMD in the alendronate-treated group were lower compared with the changes in the calcium-only group in the same regions of interest at the same follow-up time. In the proximal femur, the mean BMD decrease was 17.1% in the calcium-only group, whereas in the alendronate-treated group the decrease was only 0.9% (p = 0.019). The mean periprosthetic BMD change was also significantly different in the total periprosthetic area between the study groups at the end of the follow-up (calcium-only group -9.9% vs. alendronate-treated group -2.6%; p = 0.019). Alendronate therapy led to a significant reduction in periprosthetic bone loss after primary uncemented THA compared with the changes found in patients without therapy. This kind of bone response may improve the support of the prosthesis and may result in better survival of the prosthesis. However, in this study the follow-up time was too short and the study population was too small to make any long-term conclusions as to the prognosis for THA patients treated with alendronate.


Subject(s)
Bone Density/drug effects , Bone Resorption/drug therapy , Bone Resorption/etiology , Hip Prosthesis/adverse effects , Aged , Bone Cements , Bone Resorption/metabolism , Calcium, Dietary/administration & dosage , Female , Humans , Male , Middle Aged , Prospective Studies , Prosthesis Failure
5.
J Bone Miner Res ; 16(6): 1056-61, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11393782

ABSTRACT

Insertion of a metallic implant into the femur changes bone loading conditions and results in remodeling of femoral bone. To quantify changes in bone mass after uncemented total hip arthroplasty (THA), we monitored femoral bone with dual-energy X-ray absorptiometry (DXA). The periprosthetic bone mineral density (BMD) was measured with Lunar DPX densitometry in seven Gruen zones and the total periprosthetic area at scheduled time intervals in 22 patients during a 3-year follow-up. BMD decreased significantly almost in all Gruen zones during the first 3 months, ranging from 3.4% to 14.4% (p < 0.05 top < 0.001). At the end of the first year, the most remarkable decrease in BMD was found in the calcar (zone 7; -22.9%). During the second postoperative year, a slight restoration of periprosthetic bone mass was recorded. During the third year, no significant changes in BMD were found. The preoperative BMD was the only factor that was significantly related to the periprosthetic bone loss. Clearly, the early periprosthetic bone loss noticed during the 3 months after THA is caused by mainly limited weight bearing to the operated hip and stress shielding. We suggest that the restoration of bone mass is a sign of successful osteointegration between bone and metallic implant. DXA is a suitable tool to follow the bone response to prosthetization and will increase our knowledge on the behavior of bone after THA.


Subject(s)
Absorptiometry, Photon/methods , Arthroplasty, Replacement, Hip/methods , Bone Density , Femur/physiology , Aged , Female , Femur/diagnostic imaging , Follow-Up Studies , Humans , Male , Middle Aged , Prospective Studies
6.
Circulation ; 96(4): 1185-91, 1997 Aug 19.
Article in English | MEDLINE | ID: mdl-9286948

ABSTRACT

BACKGROUND: Immunoreactive insulin has been shown to predict the development of parasympathetic autonomic neuropathy. It is possible that constituents of immunoreactive insulin could explain this association. In this cross-sectional study, the relationship of specific insulin, C-peptide, and proinsulin with autonomic nervous dysfunction was evaluated in 57 NIDDM patients and 108 control subjects. METHODS AND RESULTS: The frequency-domain analysis of heart rate variability was determined by using spectral analysis from stationary regions of registrations while the subjects breathed spontaneously in a supine position. Total power was divided into three frequency bands: low (0 to 0.07 Hz), medium (MFP, 0.07 to 0.15 Hz), and high (HFP, 0.15 Hz to 0.50 multiplied by the frequency equal to the mean RR interval). In NIDDM patients, total power, the three frequency bands (P<.001 for each), and the MFP/HFP ratio (P=.016), which expresses sympathovagal balance, were reduced compared with control subjects. Fasting proinsulin (r(s)=-.324, P=.014 for diabetics and r(s)=-.286, P=.003 for control subjects), C-peptide (r(s)=-.492, P<.001 for diabetics and r(s)=-.304, P=.001 for control subjects), and total immunoreactive insulin (r(s)=-.291, P=.028 for diabetics and r(s)=-.228, P=.017 for control subjects) were inversely related to MFP/HFP. For proinsulin and C-peptide the results did not change after controlling for the effects of age, body mass index, and fasting glucose. CONCLUSIONS: Both proinsulin and C-peptide levels were significantly associated with the sympathovagal balance of autonomic nervous function in NIDDM patients and control subjects, but this study cannot determine whether these compounds are directly involved in autonomic nervous dysfunction.


Subject(s)
Autonomic Nervous System Diseases/etiology , C-Peptide/blood , Diabetes Mellitus, Type 2/blood , Heart Rate , Proinsulin/blood , Aged , Autonomic Nervous System Diseases/physiopathology , Cross-Sectional Studies , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/physiopathology , Electrocardiography/methods , Female , Follow-Up Studies , Humans , Insulin/blood , Least-Squares Analysis , Male , Middle Aged , Reference Values
SELECTION OF CITATIONS
SEARCH DETAIL
...